Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lacosamide for familial erythromelalgia due to SCN9A mutation
jRCTs071180055Recruiting
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lacosamide in familial erythromelalgia (FE). Primary endpoint: PI-NRS change at 16 weeks. Started Aug 2017; status: recruiting.
02
Drugs
lacosamide
03
Conditions
familial erythromelalgia (FE)
Beyond the preview
Go deeper on jRCTs071180055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180055.